given from day −9 to day −6 prior to transplantation, and i.v. cyclophosphamide (4 × 50 mg/kg body weight) given from day −5 to day −2. Cyclosporin A (serum level 300-This case report shows reversible brain MRI changes probably associated with acyclovir toxicity. So far, 400 ng/ml) was started on day −1. Short-term low-dose methotrexate (15 mg/m 2 on day 1; 10 mg/m 2 on days 3 and neuroimaging in acyclovir toxicity had been negative or uninformative. A 12-year-old girl developed focal sec-6) was administered. The patient was given prophylactic i.v. acyclovir (from day −8 before transplantation, 3 × ondary generalizing epileptic fits following 4 weeks of prophylactic administration of acyclovir (3 × 10 mg/kg 10 mg/kg body weight, the dose was reduced to 2 × 10 mg/kg body weight on day +18 because of renal impairbody weight/day i.v.) on day +22 after allogeneic peripheral blood stem cell transplantation for CML. Infective ment with increasing creatinine levels). Because of subfebrile temperatures during aplasia, a 10-day course of causes were excluded. Brain MRI demonstrated multiple gadolinium-enhancing areas with impairment of piperacillin/tazobactam was given from day +3 to day +17. From day +18 to +32 fluconazole (400 mg/day) was given the blood-brain barrier in cortical and subcortical regions. Clinical symptoms and neuroimaging patholdue to Candida albicans in throat and anal swabs. Repeated blood cultures remained negative and the patient was not ogy resolved completely within 9 days of acyclovir withdrawal.
oedema. A brain MRI scan was performed on day +22 showing a lesion at the site of the possible epileptogenic focus in the T1 and T2 scans, and multiple small lesions Case report over both hemispheres in the subcortical regions with gadolinium contrast (Figure 1a and b) in T1 weighting suggest-A 12-year-old girl underwent related HLA-identical (class ing an impairment of the blood-brain barrier. A repeat MRI I and DR and DQ antigens) allogeneic stem cell transplanon day +25 did not show the gadolinium-positive areas any tation for Philadelphia chromosome-positive CML in the more; the left parieto-occipital focus was still visible. On accelerated stage. There was no history of epilepsy or other day +31 the MRI changes had completely resolved with relevant past medical history. IgM serology prior to stem and without gadolinium contrast (Figure 1c and d) . A brain cell transplantation was negative for CMV, HSV and HIV CT scan prior to BMT had been normal, a brain CT scan in both donor and recipient. CMV and HSV IgG were posiperformed on day +23 showed the focal lesion visible on tive in the recipient. The myeloablative conditioning regithe first MRI scan but no contrast medium (Iodine, Optiray men included oral busulfan (4 × 4 mg/kg body weight) 300, Mallinckrodt, Hennef, Germany) positive lesions. Two lumbar punctures (on day +22 and +28) were negative (pandy negative, no raised cell or protein content, glu- DNA, HHV-6-DNA, JC-Virus-DNA (all determined by PCR), in the lumbar puncture from day +28 PCR for Toxoplasma gondii DNA, influenca A/B/C-RNA were negative.
Serum acyclovir levels (measured by HPLC, Laboratory there were no further fits after day +22. The patient was discharged home without antiepileptic treatment.
Discussion of viral replication markers. It is possible that these changes in some of the cases could have been influenced by toxic acyclovir effects. In view of the clinical improvement of the patient, complete
In conclusion, we suspect that gadolinium enhancing resolution of the MRI findings within 9 days of discontinuchanges of unknown aetiology with an impairment of the ation of acyclovir and other negative investigations, we susblood-brain barrier in this case can be interpreted as an pect that the described MRI findings were induced by acy-MRI correlate of acyclovir toxicity. In our case, these clovir toxicity.
changes were fully reversible within 9 days of acyclovir As previously described, 5 acyclovir levels and clearance withdrawal. This has not been reported previously. Investidepend on renal function and acyclovir itself impairs gations for infective causes of bacterial or viral origin renal function.
explaining the neuroimaging pathology had been negative. The acyclovir levels measured in our patient were within
In the differential diagnosis of MRI brain changes under expected limits. There seems to be no clear threshold for the administration of acyclovir it should be considered, that neurotoxic acyclovir side-effects. 6 The prolonged high-dose neuroimaging pathology with impairment of the bloodacyclovir administration in BMT patients in combination brain barrier may represent neurotoxicity rather than with other drugs may, however, increase the risk of toxic infection. side-effects.
In a case report 5 on suspected acyclovir neurotoxicity in combination with end stage renal failure, post-mortem References findings were those of a metabolic gliopathy in the cerebral cortex grey matter. In this case of a 72-year-old woman
